Robert (Bob) Coffey

Ken Lau, PhD, left, and Bob Coffey, MD, have made several important discoveries about colorectal cancer that are aiding the search for new, more effective therapies. (photo by Erin O. Smith)

Colorectal cancer ‘cartography’ reveals an avenue to improved immunotherapy

Vanderbilt University Medical Center researchers have discovered why most colorectal tumors escape detection and destruction by the body’s immune system.

Bob Coffey, MD

Vanderbilt research presented at Cancer Moonshot meet

Vanderbilt Colorectal cancer expert Bob Coffey, MD, was recently invited to present his research to representatives of President Joe Biden’s reignited Cancer Moonshot initiative.

A ‘supermere’ method for biomarker discovery

Vanderbilt researchers have developed a method for isolating extracellular vesicles and nanoparticles — a complex transport system involved in health and disease — which will improve biomarker discovery and the identification of therapeutic targets.

Colon cancer researchers awarded NCI grant for study of early lesions

Vanderbilt researchers are studying precancerous lesions and early cancers in the colon, with the goal of developing new ways to prevent colorectal cancer, the nation’s second leading cancer killer.

Award winners and faculty pose for a photo before last week’s School of Medicine Spring Faculty Meeting.

Faculty awards honor teaching, clinical, research excellence

The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.

x-ray of stomach

New prognosis predictor and target for gastric cancer

The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.

1 2 3